Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475275 | 0.91 | CRHR1 (0.47) | CRHR1HDAC3HDAC1HDAC2CACNA2D1 | |
| SCHEMBL6202690 | 0.88 | CRHR1 (0.46) | CRHR1HDAC3HDAC1HDAC2CACNA2D1 | |
| SCHEMBL7482544 | 0.83 | CRHR1 (0.52) | CRHR1TLR7 | |
| SCHEMBL7473622 | 0.82 | CRHR1 (0.58) | CRHR1TLR7 | |
| SCHEMBL7472049 | 0.82 | CRHR1 (0.56) | CRHR1ADORA3TLR7 | |
| SCHEMBL4924779 | 0.81 | CRHR1 (0.58) | CRHR1ADORA3TLR7 | |
| SCHEMBL7478304 | 0.80 | CRHR1 (0.41) | CRHR1TLR7 | |
| SCHEMBL5423381 | 0.80 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL7606978 | 0.79 | CRHR1 (0.59) | CRHR1HDAC3HDAC1HDAC2 | |
| SCHEMBL6203377 | 0.79 | CRHR1 (0.53) | CRHR1ADORA3TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885HDAC3 846/4885HDAC1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.